Posted by admin on Jul 17th, 2022

Alphatec (NASDAQ:ATEC – Get Rating) ‘s stock had its “buy” rating reissued by research analysts at Lake Street Capital in a research report issued on Friday, The Fly reports. They currently have a $9.00 price objective on the medical technology company’s stock. Lake Street Capital’s price objective would indicate a potential upside of 34.93% from the company’s current price.

ATEC has been the subject of several other reports. Needham & Company LLC decreased their target price on Alphatec from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, May 26th. HC Wainwright raised their target price on Alphatec from $19.00 to $20.00 in a research report on Friday, May 6th. Finally, StockNews.com started coverage on Alphatec in a report on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alphatec currently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

NASDAQ ATEC opened at $6.67 on Friday. The firm has a market capitalization of $678.74 million, a P/E ratio of -4.04 and a beta of 1.62. The business has a fifty day simple moving average of $7.24 and a 200 day simple moving average of $9.80. Alphatec has a 12 month low of $5.73 and a 12 month high of $15.34. The company has a current ratio of 2.62, a quick ratio of 1.76 and a debt-to-equity ratio of 7.78.

Alphatec (NASDAQ:ATEC – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The medical technology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.14). The company had revenue of $70.93 million during the quarter, compared to analysts’ expectations of $67.72 million. Alphatec had a negative net margin of 60.83% and a negative return on equity of 147.10%. On average, analysts predict that Alphatec will post -1.31 EPS for the current fiscal year.

In other news, EVP Craig E. Hunsaker sold 70,000 shares of Alphatec stock in a transaction dated Wednesday, June 1st. The stock was sold at an average price of $7.16, for a total transaction of $501,200.00. Following the completion of the sale, the executive vice president now owns 1,362,229 shares in the company, valued at approximately $9,753,559.64. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder Paul Segal bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 14th. The stock was bought at an average price of $6.95 per share, for a total transaction of $347,500.00. Following the transaction, the insider now directly owns 288,825 shares of the company’s stock, valued at approximately $2,007,333.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Craig E. Hunsaker sold 70,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $7.16, for a total value of $501,200.00. Following the completion of the sale, the executive vice president now owns 1,362,229 shares of the company’s stock, valued at approximately $9,753,559.64. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 79,700 shares of company stock worth $563,300 and sold 300,000 shares worth $2,339,500. Corporate insiders own 33.93% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new position in Alphatec in the 1st quarter worth approximately $66,000. Amplius Wealth Advisors LLC purchased a new position in Alphatec in the 4th quarter worth approximately $68,000. Cutler Group LP purchased a new position in Alphatec in the 4th quarter worth approximately $102,000. SG Americas Securities LLC purchased a new position in Alphatec in the 1st quarter worth approximately $108,000. Finally, Walleye Trading LLC purchased a new position in Alphatec in the 1st quarter worth approximately $124,000. 53.52% of the stock is owned by hedge funds and other institutional investors.

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.

The Goldman Sachs Group Lowers Analog Devices (NASDAQ:ADI) Price Target to $167.00

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Down 37.8% in June